On March 31, 2021 Hwasun Chonnam National University Hospital and a bio venture company founded by the hospital’s medical staff are joining hands to accelerate the development of radioactive pharmaceuticals for cancer diagnosis and treatment. Hwasun Chonnam National University Hospital recently signed an MOU with CNCure Co., Ltd (Press release, Hwasun Chonnam National University Hospital, MAR 31, 2021, View Source [SID1234649031]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through this business agreement, the two organizations promised to cooperate and exchange information on the development of radiopharmaceuticals and the progress of clinical trials, cooperate in the use of in-house GMP facilities for the production of radiopharmaceuticals for clinical trials, and share medical and pharmaceutical academic knowledge and information necessary for conducting clinical studies.
C&Cure Co., Ltd. is a bio venture company established in 2019 by the medical staff of Hwasun Chonnam National University Hospital and researchers from Chonnam National University College of Medicine.
The main business is the development of cancer-targeting bacteria-based anticancer treatment, and the development of radiopharmaceuticals for the diagnosis and treatment of infectious diseases and cancer. As of now, 8.8 billion won in private investment and 1 billion won in government-local government research projects have been secured. Clinical trials of two types of radiopharmaceuticals for the diagnosis of cancer and infectious diseases are scheduled to begin this year.
Professor Min Jeong-jun, the CEO, is also the president of the Korean Society of Nuclear Medicine and is a world authority in the field of theranostics, which performs imaging diagnosis and treatment simultaneously.
He has developed the world’s first drug-releasing Salmonella and E. coli, opening a new horizon in cancer treatment technology. He has also developed radioactive medicines that can precisely attack malignant melanoma, lung cancer, and colon cancer. While leading the Molecular Imaging Theranostics Research Institute, he has published over 200 papers domestically and internationally, and holds dozens of patents in related fields.
CEO Min said, "I am reassured that we have been able to collaborate on research and development with Hwasun Chonnam National University Hospital, which is leading the next-generation medical care and conquering cancer," and added, "We will join forces to accelerate the development of radioactive pharmaceuticals as well as personalized precision cancer treatment for patients."
President Shin Myeong-geun responded, "Like ‘Vaccell Bio,’ which was founded in 2010 by some of our medical staff and is making a name for itself in the development of anticancer immune cell therapy, the establishment of a venture company can be a catalyst for strengthening our clinical treatment capabilities and medical competitiveness." He added, "We will do our best to enable more efficient cancer diagnosis and treatment through strong industry-hospital cooperation."